BioSpace News Archive

OliX Pharmaceuticals, Inc. announced today that it has eceived approval from the Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical trial of OLX72021, a treatment for androgenic alopecia, also known as male-pattern baldness.

Processa Pharmaceuticals, Inc. today announced that it will host a conference call and live webcast on March 30, 2023 at 4:30 p.m. EST to discuss its 2022 results and provide an update on its clinical pipeline for 2023.

Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.

Innate Pharma SA reported its consolidated financial results1 for the year ending December 31, 2022.

Anaveon, a clinical stage, immuno-oncology company, announced that it will present a poster on ANV600 at the American Association for Cancer Research 23rd Annual Meeting being held from Friday, April 14, 2023, to Wednesday, April 19, 2023, in Orlando, Florida.

Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for its novel cell therapy, Vyznova™, for the treatment of bullous keratopathy of the cornea.

Applied Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.

NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.